Navigation Links
H3 Biomedicine and Selvita Announce Strategic Collaboration to Develop Precision Cancer Medicines
Date:9/16/2013

CAMBRIDGE, Mass. and KRAKOW, Poland, Sept. 16, 2013 /PRNewswire/ -- H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision oncology treatments, and Selvita (PL: SLV), one of the largest drug discovery companies in Eastern Europe, announced today that they have entered into a strategic collaboration to develop breakthrough precision medicines for cancers. The companies will seek to validate the importance and druggability of several kinase targets in specific genetic contexts and to generate multiple novel drug candidates against those targets. 

(Logo: http://photos.prnewswire.com/prnh/20120430/NY96379LOGO )

Recent advances in human cancer genomics have revealed novel target opportunities that will enable new approaches to developing cancer medicines. H3 Biomedicine has built extensive and proprietary target acumen. It has also implemented a set of unique tools and research engines in the areas of cancer genomics, bioinformatics and target validation to lend biological insight to genomic findings. These capabilities will help to accelerate its collaborative drug discovery and development efforts. Selvita started its first kinase discovery programs in 2008 and, over the last five years, has built a premium scientific team with one of the world's most robust kinase discovery platforms. Together, the two companies have the know-how to leverage data from the new target opportunities revealed through cancer genomics.

"Our goal at H3 Biomedicine is to – in a very focused way – utilize the genomic information from public and proprietary data sets to identify and validate highly relevant cancer genes and to develop effective therapies against those targets," stated

SOURCE H3 Biomedicine Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cellular Biomedicine Group Reports Second Quarter and First Half 2013 Financial Results and Business Highlights
2. Cellular Biomedicine Group Announces Expansion in the Osteoarthritis and Rheumatoid Arthritis Market
3. Cellular Biomedicine Group Announces Appointment of Corporate Controller
4. Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis
5. Cellular Biomedicine Group Provides Update and 2013 Milestones
6. Cellular Biomedicine Group Appoints Dr. Jianping Dai to the Board of Directors
7. Cellular Biomedicine Group President Presents Keynote Address at New York Stem Cell Summit
8. Cellular Biomedicine Group Announces ISO 9001:2008 Certification and ISO-14644 Cleanroom Certification
9. EastBridge Investment Group Announces Completion of its Merger with Cellular Biomedicine Group - Shareholder Conference Call to be held February 8th
10. H3 Biomedicine Expands Cambridge Facilities, Doubles Employee Base as Scientific Program Advances
11. A 300 Million Euro Boost for Biomedicine in Berlin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... , April 20, 2015 Stent ... clots from vessels in the brain reduced disability ... by Tudor Jovin, MD, President of the Society ... "This is a giant step forward that ... treatment of stroke patients," said Jovin, who is ...
(Date:4/20/2015)... Columbia and MENLO PARK, ... DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and ... and commercializing proven cancer therapies in new orphan ... the 106th Annual Meeting of the American ... on the potential for its lead product candidate ...
(Date:4/20/2015)... 20, 2015 PMG Research, Inc ... clinical research site: PMG Research of Christie Clinic. Effective ... the clinical research department at Christie Clinic ... to a second region within the United States. This ... enhances PMG’s access to an additional 80,000 patients. For ...
(Date:4/20/2015)... FORT WORTH, Texas , April 20, 2015 /PRNewswire/ ... by orthopedic surgeons for healing bone injuries. The orthobiologics ... of growth opportunities for its stakeholders. The global orthobiologics ... analysis and forecast of revenue. The global orthobiologics market ... projected to reach $7,900.2 million by 2019, at a ...
Breaking Biology Technology:SVIN President Tudor Jovin, MD, Co-Leads Groundbreaking Stroke Study In The New England Journal Of Medicine 2SVIN President Tudor Jovin, MD, Co-Leads Groundbreaking Stroke Study In The New England Journal Of Medicine 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 2DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 4DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 5PMG Research Announces the Formation of its 12th Site in Champaign-Urbana, IL 2PMG Research Announces the Formation of its 12th Site in Champaign-Urbana, IL 3Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 2Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 3
... Company now officially following an FDA 510(k) (Pre-Market Notification), Pathway for ... ... Human Appendicitis, CASTLE ROCK, Colo., Nov. 27 AspenBio Pharma,Inc. ... of novel drugs and diagnostics for animals and humans, has,received an ...
... Shamir,Optical Industry Ltd. (Nasdaq: SHMR ) ("Shamir"), a ... ophthalmic lens,market, today announced unaudited financial results for the ... ended September 30, 2007, revenues increased by 28.5%,to $30.9 ... of 2006.,Gross profit for the quarter increased by 25.3% ...
... Masimo receives approval from Ministry of Health, Labor and Welfare ... carbon ... monoxide levels in the blood, IRVINE, Calif., ... Motion and Low Perfusion pulse,oximetry, today announced approval of the ...
Cached Biology Technology:AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test 2AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test 3AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test 4Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 2Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 3Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 4Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 5Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 6Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 7Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 8Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 9Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 10Masimo Corporation Given Approval to Market the Masimo Rad-57 Pulse CO-Oximeter in Japan 2Masimo Corporation Given Approval to Market the Masimo Rad-57 Pulse CO-Oximeter in Japan 3Masimo Corporation Given Approval to Market the Masimo Rad-57 Pulse CO-Oximeter in Japan 4
(Date:4/20/2015)... , April 20, 2015 Huntington Memorial Hospital ... to implant a new miniaturized, wireless monitoring sensor to ... the first and only FDA-approved heart failure monitoring device ... when used by physicians to manage heart failure. ... is implanted in the pulmonary artery (PA) during a ...
(Date:4/20/2015)... , April 20, 2015 The ... Glenbeigh Records Management (GRM), Ireland,s ... Dubai Islamic Bank. Having built up an impressive track record ... a leading player within the records management sector in ... to double is GCC staffbase and employ a further eight ...
(Date:4/17/2015)... 17, 2015 Increasing ... technological advancement to drive biometric systems market in ...   According to a recently released ... &  Opportunities, 2020 ", biometric systems market in ... growth at CAGR of over 22% through 2020. ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3
... A study that relates global energy use to economic ... , finds strong correlations between these two measures both ... leads the study,s authors to infer that energy use ... increase in energy supply will be required to meet ...
... French . Scientists have discovered direct evidence of ... ammonites, distant relatives of squids, octopuses and cuttlefishes. The discovery ... 65.5 million years ago, at the end of the Cretaceous. ... fossils but until now, there has been no experimental evidence ...
... native perennials instead of corn in the Midwest,s rolling ... University research suggests. Federal mandates and market forces ... biologist Bruce Robertson says, but the environmental consequences of ... are a serious concern. Ethanol in America is ...
Cached Biology News:Study finds energy limits global economic growth 2Ammonites' last meal: New light on past marine food chains 2Ammonites' last meal: New light on past marine food chains 3Biofuel grasslands better for birds than ethanol staple corn, researchers find 2
... Each vial contains 200 g of ... receptor sequence (C-terminal amino acids 380-402; GLTPSAWEASSLRSSRHSGLSHF. ... an antigen for production of Cayman's EP1 ... can be used in conjunction with this ...
Anti-ZFP200 Family: Zinc Finger Peptide Sequence: CGKSFNHKTNLNKHER...
Complete cell culture media with cytokines...
Consists of 4 separate 100mM solutions (ATP,GTP,CTP and UTP pH 7.5) as sodium salts. 98% Pure by HPLC...
Biology Products: